Targeted Imaging and Therapy for Cancer using the Fibroblast Activated Proteins (FAP)

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	2020-LOW-68793
Categories	Medical/Health Pharmaceuticals
Keywords	Cancer Cancer Therapy Fibroblast Fibrotic Diseases Imaging Medical/Health
Public Abstract	Researchers at Purdue University have developed a new class of ligands as drug candidates and imaging agents for targeting FAP-containing cancer-associated fibroblasts (CAFs) and myofibroblasts in cancers. Traditional diagnostics and therapeutics used to identify and treat FAP-positive cancers and fibrotic diseases are often ineffective because they are administered off-target. Patients with FAP-positive cancers are currently given a long-term survival rate of less than fifty percent, leaving an unmet need to develop imaging and therapeutic tools. Purdue researchers have optimized the abundant presence of FAP on the surfaces of diseased cells to develop an off-the-shelf class of ligands for FAP-targeted drug delivery and imaging. In addition, the new method can improve patient care by targeting drug delivery with improved specificity and less toxicity. Advantages: -Improved specificity -Detects wider range of cancers -Reduced non-specific toxicity Potential Applications: -Targeted treatment of cancer patients by reducing tumor burden -Imaging and treatment of other fibrotic diseases
People	Low, Philip Stewart (Project leader) Mukkamala, Ramesh Srinivasarao, Madduri
Intellectual Property	Application Date Aug 16, 2022 Type Foreign, Non-PCT Country of Filing Hong Kong Patent Number (None) Issue Date (None) Application Date Apr 11, 2022 Type NATL-Patent Country of Filing India Patent Number (None) Issue Date (None) Application Date Mar 17, 2022 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Europe Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Australia Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Canada Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing China Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Japan Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing South Korea Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Israel Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Singapore Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing New Zealand Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Brazil Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Eurasian Patent Organization Patent Number (None) Issue Date (None) Application Date Sep 17, 2020 Type NATL-Patent Country of Filing Mexico Patent Number (None) Issue Date (None) Application Date Sep 17, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org